Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) levels and IL-6, TNF-polymorphisms in children with thrombosis

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 1, 2008, Pages 26-31

  Unal, Selma ^a   Gumruk, Fatma ^a   Aytac, Selin ^a   Yalnzoglu, Dilek ^a   Gurgey, Aytemiz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Children; Cytokine; Interleukin 6; Thrombosis; Tumour necrosis factor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANAMNESIS; ARTERY THROMBOSIS; ARTICLE; CHILD; CONTROLLED STUDY; EVALUATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFANT; INFECTION; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; THROMBOSIS; TURKEY (REPUBLIC); VEIN THROMBOSIS;

ALLELES; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INFECTION; INTERLEUKIN-6; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; THROMBOSIS; TUMOR NECROSIS FACTOR-ALPHA; TURKEY;

EID: 37849039790     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31815b1a89     Document Type: Article

References (39)

1. Richardson MW, Allen GA, Monahan PE. Thrombosis in children: current perspective and distinct challenges. Thromb Haemost. 2002;88:900-911.
2. Dahlback B. Blood coagulation. Lancet. 2000;355:1627-1632.
3. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83:1251-1257.
4. Gurgey A, Aslan D. Outcome of noncatheter-related thrombosis in children: influence of underlying or coexisting factors. J Pediatr Hematol Oncol. 2001;23:159-164.
5. Joseph L, Fink LM, Hauer-Jensen M. Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood Coagul Fibrinolysis. 2002;13:105-116.
6. Mantovani A, Sozzani S, Vecchi A, et al. Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb Haemost. 1997;78:406-414.
7. Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003;1:1343-1348.
8. Tapper H, Herwald H. Modulation of hemostatic mechanism in bacterial infectious disease. Blood. 2000;96:2329-2337.
9. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104:100-106.
10. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195-3199.
11. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001;21:1458-1463.
12. Alam SE, Nasser SS, Fernainy KE, et al. Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol. 2004;4:166-170.
13. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
14. Keaney JF Jr, Vita JA. The value of inflammation for predicting unstable angina. N Engl J Med. 2002;347:55-57.
15. Sryjanen J, Valtonen VV, Iivanainen M, et al. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br Med J (Clin Res Ed). 1988;296:1156-1160.
16. Grau AJ, Buggle F, Heindl S, et al. Recent infection as a risk factor for cerebrovascular ischemia. Stroke. 1995;26:373-379.
17. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
18. Poort SR, Rosendaal FR, Reistma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
19. Gurgey A, Mesci L. The prevalence of factor V Leiden (1691 G-A) mutation in Turkey. Turk J Pediatr. 1997;39:313-315.
20. Gurgey A, Hicsonmez G, Parlak H, et al. Prothrombin gene 20210 G-A mutation in Turkish patients with thrombosis. Am J Hematol. 1998;59:179-180.
21. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874-877.
22. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 2005;94:362-365.
23. Bierhaus A, Zhang Y, Deng Y, et al. Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J Biol Chem. 1995;270:26419-26432.
24. Brown K, Luddington R, Baglin T. A common polymorphism in the tumour necrosis factor-alpha gene associated with high TNF levels is not a risk factor for venous thromboembolism. Br J Haematol. 1998;101:480-482.
25. Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P, et al. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigen. 2004;64:469-472.
26. Tseng FC, Brown EE, Maiese EM, et al. Polymorphisms in cytokine genes and risk of Helicobacter pylori infection among Jamaican children. Helicobacter. 2006;11:425-430.
27. Alakulppi NS, Kyllonen LE, Salo HM, et al. The impact of donor cytokine gene polymorphisms on the incidence of cytomegalovirus infection after kidney transplantation. Transpl Immunol. 2006;16:258-262.
28. Fishman D, Faulds G, Jefffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369-1376.
29. Tang GJ, Huang SL, Yien HW, et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med. 2000;28:2733-2736.
30. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1722.
31. Xing A, Gauldie J, Cox G, et al. Il-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory response. J Clin Invest. 1998;101:311-320.
32. Basso F, Lowe GD, Rumley A, et al. Interleukin-6 -174G′C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol. 2002;22:599-604.
33. Vormittag R, Hsieh K, Kaider A, et al. Interleukin-6 and interleukin-6 promoter polymorphism (-174) G′C in patients with spontaneous venous thromboembolism. Thromb Haemost. 2006;95:802-806.
34. Akar N. Molecular approach to Turkish pediatric stroke patients. Turk J Haematol. 2002;19:245-253.
35. Rosalki SB. C-reactive protein. Int J Clin Pract. 2001;55:269-270.
36. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992;35:982-984.
37. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990;65:168-172.
38. Jurado R, Riberio M. Possible role of systemic inflammatory reaction in vascular access thrombosis. South Med J. 1999;92:877-881.
39. Vormittag R, Vukovich T, Schonauer V, et al. Basal high-sensitivity-C- reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost. 2005;93:488-493.